FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291320147> ?p ?o ?g. }

• W4291320147 endingPage "4391" @default.
• W4291320147 startingPage "4385" @default.
• W4291320147 abstract "Abstract Purpose: The phase II CAPTIVATE study investigated first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia in two cohorts: minimal residual disease (MRD)-guided randomized treatment discontinuation (MRD cohort) and fixed duration (FD cohort). We report tumor debulking and tumor lysis syndrome (TLS) risk category reduction with three cycles of single-agent ibrutinib lead-in before initiation of venetoclax using pooled data from the MRD and FD cohorts. Patients and Methods: In both cohorts, patients initially received three cycles of ibrutinib 420 mg/day then 12 cycles of ibrutinib plus venetoclax (5-week ramp-up to 400 mg/day). Results: In the total population (N = 323), the following decreases from baseline to after ibrutinib lead-in were observed: percentage of patients with a lymph node diameter ≥5 cm decreased from 31% to 4%, with absolute lymphocyte count ≥25 × 109/L from 76% to 65%, with high tumor burden category for TLS risk from 23% to 2%, and with an indication for hospitalization (high TLS risk, or medium TLS risk and creatinine clearance &lt;80 mL/minute) from 43% to 18%. Laboratory TLS per Howard criteria occurred in one patient; no clinical TLS was observed. Conclusions: Three cycles of ibrutinib lead-in before venetoclax initiation provides effective tumor debulking, decreases the TLS risk category and reduces the need for hospitalization for intensive monitoring for TLS." @default.
• W4291320147 created "2022-08-14" @default.
• W4291320147 creator A5006104041 @default.
• W4291320147 creator A5008054206 @default.
• W4291320147 creator A5019892839 @default.
• W4291320147 creator A5034517642 @default.
• W4291320147 creator A5035890812 @default.
• W4291320147 creator A5047971271 @default.
• W4291320147 creator A5053787554 @default.
• W4291320147 creator A5054841750 @default.
• W4291320147 creator A5055100327 @default.
• W4291320147 creator A5082662801 @default.
• W4291320147 creator A5087877679 @default.
• W4291320147 creator A5089428686 @default.
• W4291320147 creator A5090559016 @default.
• W4291320147 creator A5090615083 @default.
• W4291320147 date "2022-08-08" @default.
• W4291320147 modified "2023-10-12" @default.
• W4291320147 title "Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts" @default.
• W4291320147 cites W2075875145 @default.
• W4291320147 cites W2122479144 @default.
• W4291320147 cites W2142099365 @default.
• W4291320147 cites W2580821712 @default.
• W4291320147 cites W2808653175 @default.
• W4291320147 cites W2914942030 @default.
• W4291320147 cites W2940351544 @default.
• W4291320147 cites W2946882253 @default.
• W4291320147 cites W2948436219 @default.
• W4291320147 cites W3132537256 @default.
• W4291320147 cites W3171790279 @default.
• W4291320147 cites W3201468520 @default.
• W4291320147 cites W3203683811 @default.
• W4291320147 cites W3212343548 @default.
• W4291320147 cites W3213453908 @default.
• W4291320147 cites W3216082330 @default.
• W4291320147 cites W4285034472 @default.
• W4291320147 doi "https://doi.org/10.1158/1078-0432.ccr-22-0504" @default.
• W4291320147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35939599" @default.
• W4291320147 hasPublicationYear "2022" @default.
• W4291320147 type Work @default.
• W4291320147 citedByCount "1" @default.
• W4291320147 countsByYear W42913201472023 @default.
• W4291320147 crossrefType "journal-article" @default.
• W4291320147 hasAuthorship W4291320147A5006104041 @default.
• W4291320147 hasAuthorship W4291320147A5008054206 @default.
• W4291320147 hasAuthorship W4291320147A5019892839 @default.
• W4291320147 hasAuthorship W4291320147A5034517642 @default.
• W4291320147 hasAuthorship W4291320147A5035890812 @default.
• W4291320147 hasAuthorship W4291320147A5047971271 @default.
• W4291320147 hasAuthorship W4291320147A5053787554 @default.
• W4291320147 hasAuthorship W4291320147A5054841750 @default.
• W4291320147 hasAuthorship W4291320147A5055100327 @default.
• W4291320147 hasAuthorship W4291320147A5082662801 @default.
• W4291320147 hasAuthorship W4291320147A5087877679 @default.
• W4291320147 hasAuthorship W4291320147A5089428686 @default.
• W4291320147 hasAuthorship W4291320147A5090559016 @default.
• W4291320147 hasAuthorship W4291320147A5090615083 @default.
• W4291320147 hasBestOaLocation W42913201471 @default.
• W4291320147 hasConcept C121608353 @default.
• W4291320147 hasConcept C126322002 @default.
• W4291320147 hasConcept C141071460 @default.
• W4291320147 hasConcept C143998085 @default.
• W4291320147 hasConcept C2776694085 @default.
• W4291320147 hasConcept C2777938653 @default.
• W4291320147 hasConcept C2778461978 @default.
• W4291320147 hasConcept C2778715236 @default.
• W4291320147 hasConcept C2779675984 @default.
• W4291320147 hasConcept C2779788671 @default.
• W4291320147 hasConcept C2779823535 @default.
• W4291320147 hasConcept C2779878957 @default.
• W4291320147 hasConcept C2780427987 @default.
• W4291320147 hasConcept C2781100745 @default.
• W4291320147 hasConcept C2908647359 @default.
• W4291320147 hasConcept C71924100 @default.
• W4291320147 hasConcept C99454951 @default.
• W4291320147 hasConceptScore W4291320147C121608353 @default.
• W4291320147 hasConceptScore W4291320147C126322002 @default.
• W4291320147 hasConceptScore W4291320147C141071460 @default.
• W4291320147 hasConceptScore W4291320147C143998085 @default.
• W4291320147 hasConceptScore W4291320147C2776694085 @default.
• W4291320147 hasConceptScore W4291320147C2777938653 @default.
• W4291320147 hasConceptScore W4291320147C2778461978 @default.
• W4291320147 hasConceptScore W4291320147C2778715236 @default.
• W4291320147 hasConceptScore W4291320147C2779675984 @default.
• W4291320147 hasConceptScore W4291320147C2779788671 @default.
• W4291320147 hasConceptScore W4291320147C2779823535 @default.
• W4291320147 hasConceptScore W4291320147C2779878957 @default.
• W4291320147 hasConceptScore W4291320147C2780427987 @default.
• W4291320147 hasConceptScore W4291320147C2781100745 @default.
• W4291320147 hasConceptScore W4291320147C2908647359 @default.
• W4291320147 hasConceptScore W4291320147C71924100 @default.
• W4291320147 hasConceptScore W4291320147C99454951 @default.
• W4291320147 hasIssue "20" @default.
• W4291320147 hasLocation W42913201471 @default.
• W4291320147 hasLocation W42913201472 @default.
• W4291320147 hasLocation W42913201473 @default.
• W4291320147 hasLocation W42913201474 @default.
• W4291320147 hasLocation W42913201475 @default.

• next